Skip directly to content
HOME
Tafamidis is the first and only treatment that can provide both a reduction in all-cause mortality and CV-related hospitalization in patients with wild-type or hereditary ATTR-CM and a delay in neurologic impairment for stage 1 adult patients with ATTR-PN.3-5